Lineage Cell Therapeutics opened lower at $1.10, compared with its previous close of $1.11. In the last trading session, the stock traded between $0.99 and $1.13. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Lineage Cell Therapeutics is now worth
$ 40.45
Resulting in a loss of
$ 59.55 (59.55%)
Note: Past profits do not guarantee future returns.
Rating from 2 Analysts
Today's Change
$-0.12 (-10.36%)
Day High
$1.13
Day Low
$0.99
Day Open
$1.10
Prev Close
$1.11
Volume
11,95,231
1W Return
-3.86%
1M Return
4.30%
3M Return
-10.76%
6M Return
-24.05%
1Y Return
-45.33%
Market Cap ($ Mn)
252
PE Ratio
-
PB Ratio
4.61
PEG Ratio
-
ROE
-116.32%
ROCE
-76.55%
EPS (TTM)
$0.01
1 Week
-3.86%
1 Month
4.30%
3 Months
-10.76%
6 Months
-24.05%
9 Months
-44.72%
Lineage Cell Therapeutics Q3FY27 Results: Earnings call set for November 12
Lineage Cell Therapeutics will report Q3 2026 financial results on November 12, 2026. Conference call scheduled for 4:30 pm ET on the same day. Pipeline includes OpRegen (Phase 2a) and OPC1 (Phase 1/2a) cell therapies. Manufacturing operations in Jerusalem face risks from regional conflict.
7 days agoLineage Cell Therapeutics Q2 Results: Net income turns positive on warrant gains
Lineage Cell Therapeutics reported Q2 2026 net income of $1.5 million, reversing a $30.5 million loss from the prior year. The turnaround was driven by a $9.4 million non-cash gain on warrant liabilities. Operating revenues fell to $1.1 million, while cash reserves of $50.8 million support operations into Q3 2028. Clinical progress includes positive long-term data for OpRegen and advancement of the COR1 corneal therapy program.
3mo agoLineage Cell Therapeutics advances COR1 corneal program
Lineage Cell Therapeutics updated on its COR1 program, using the AlloSCOPE platform for scalable allogeneic production. The program targets corneal endothelial disease with a thaw-and-inject formulation. A conference call is scheduled for today.
4mo agoLineage Cell Therapeutics CEO to present at B. Riley summit
Lineage Cell Therapeutics, Inc. announced that CEO Brian M. Culley will present at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit on July 16, 2026, in Boston. The company is a clinical-stage biotechnology firm developing allogeneic cell therapies for serious medical conditions. Its pipeline includes programs in Phase 2a, Phase 1/2a, and preclinical stages targeting conditions such as macular degeneration, spinal cord injuries, and auditory neuropathy.
4mo agoLineage Cell Therapeutics reports Q1 2026 results, advances pipeline
Lineage Cell Therapeutics reported a Q1 2026 net loss of $4.8 million on revenues of $1.7 million, with $53.4 million in cash to fund operations into Q2 2028. The company advanced its Opregen and OPC1 programs, launched the COR1 corneal initiative, and progressed its Resonance and ILT1 manufacturing platforms.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Lineage Cell Therapeutics is now worth
$ 40.45
Resulting in a loss of
$ 59.55 (59.55%)
Note: Past profits do not guarantee future returns.
